Education
About Us
Working with TipRanks
Follow Us
Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
HOWL Stock Chart & Stats
$0.66
-$0.04(-2.90%)
At close: 4:00 PM EST
$0.66
-$0.04(-2.90%)
Day’s Range― - ―
52-Week Range$0.53 - $2.38
Previous CloseN/A
Volume113.58K
Average Volume (3M)1.22M
Market Cap
$31.73M
Enterprise Value$3.31M
Total Cash (Recent Filing)$65.71M
Total Debt (Recent Filing)$37.30M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Mar 19, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding48,540,200
10 Day Avg. Volume1,746,006
30 Day Avg. Volume1,221,642
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.87
Price to Sales (P/S)34.02
P/FCF Ratio-1.14
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.98
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$4.00Price Target Upside506.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyWTX-124 showed objective responses in heavily pretreated patients and activity extending beyond melanoma into other solid tumors, indicating single-agent tumor activity that could support broader development.
Regulatory ProgressFDA acceptance of an 18 mg recommended dose for WTX-124 along with initial guidance supporting a potential monotherapy registration pathway increases clarity on approval prospects for relapsed or refractory melanoma.
Safety ProfileFavorable tolerability for WTX-124 with no evidence of vascular leak syndrome and reduced immune-related adverse events, together with improved safety updates for the '330 program, supports the development of safer systemically deliverable therapies.
Bears Say
Data Clarity RiskConfusion around outcomes from the '124/PD-1 combination has introduced uncertainty about the clinical development pathway, potentially complicating signaling to investors and partners.
Investor SentimentSignificant share price decline driven by investor disappointment over lack of clinical or regulatory clarity for the '124/PD-1 combination has heightened market sensitivity to upcoming data and guidance.
Regulatory And Partnership RiskInsufficient clinical and regulatory insights for the combination increase the chance that regulators or potential partners will request additional studies, which could extend development timelines and raise costs.
Werewolf Therapeutics News
HOWL FAQ
What was Werewolf Therapeutics’s price range in the past 12 months?
Werewolf Therapeutics lowest stock price was $0.53 and its highest was $2.38 in the past 12 months.
What is Werewolf Therapeutics’s market cap?
Werewolf Therapeutics’s market cap is $31.73M.
When is Werewolf Therapeutics’s upcoming earnings report date?
Werewolf Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 32 days.
How were Werewolf Therapeutics’s earnings last quarter?
Werewolf Therapeutics released its earnings results on Nov 04, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.383 by $0.023.
Is Werewolf Therapeutics overvalued?
According to Wall Street analysts Werewolf Therapeutics’s price is currently Undervalued.
Does Werewolf Therapeutics pay dividends?
Werewolf Therapeutics does not currently pay dividends.
What is Werewolf Therapeutics’s EPS estimate?
Werewolf Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Werewolf Therapeutics have?
Werewolf Therapeutics has 48,540,200 shares outstanding.
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Werewolf Therapeutics reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.383. Following the earnings report the stock price went down -7.634%.
Which hedge fund is a major shareholder of Werewolf Therapeutics?
Currently, no hedge funds are holding shares in HOWL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Werewolf Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (506.06% Upside)
$4.00 (506.06% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.95%
12-Months-Change
Fundamentals
Return on Equity
-122.43%
Trailing 12-Months
Asset Growth
-39.78%
Trailing 12-Months
Company Description
Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
HOWL Stock 12 Month Forecast
Average Price Target
$4.00
▲(506.06% Upside)
Technical Analysis
CervoMed
―
NRX Pharmaceuticals
―
Kalaris Therapeutics
―
Coeptis Therapeutics Holdings
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
42.22% Insiders
3.29% Mutual Funds
0.02% Other Institutional Investors
51.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---